Pfizer News | finanzen.ch

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Orderbuch			Analysen
Historisch

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Orderbuch

Analysen

Historisch

17.02.22	Form 4 78003 (RSS)
15.02.22	Pfizer and OPKO’s Once-Weekly NGENLA™ (somatrogon) Injection Receives Marketing Authorization in European Union for Treatment of Pediatric Growth Hormone Deficiency (Businesswire)
15.02.22	European Medicines Agency Approves Pfizer’s 20-Valent Pneumococcal Conjugate Vaccine Against Invasive Pneumococcal Disease and Pneumonia in Adults (Businesswire)
14.02.22	FDA Pushes Vaccine For Children Under 5 Year Back For More Data (RTTNews)
14.02.22	Biohaven Pharma: Rimegepant Asia-Pacific Phase 3 Study Meets Co-primary Endpoints (RTTNews)
11.02.22	Pfizer and BioNTech Provide Update on Rolling Submission for Emergency Use Authorization of Their COVID-19 Vaccine in Children 6 Months Through 4 Years of Age (Businesswire)
11.02.22	Form SC 13G/A 78003 (RSS)
09.02.22	Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference (Businesswire)
08.02.22	Pfizer Q4 Adj. Profit Rises; Projects 47% Operational Growth In FY22 Adj. EPS (RTTNews)
08.02.22	Pfizer Inc. Q4 Income Advances (RTTNews)
04.02.22	Valneva Announces Further Positive Phase 2 Data For Lyme Disease Vaccine Candidate VLA15 (RTTNews)
02.02.22	GlaxoSmithKline's ViiV Healthcare Receives FDA Approval For HIV Treatment (RTTNews)
02.02.22	GlaxoSmithKline Says Gilead, ViiV Healthcare Settle Patent Dispute Over HIV Drug (RTTNews)
02.02.22	Pfizer Seeks FDA Approval For COVID-19 Vaccine In Children Under 5 Yrs (RTTNews)
01.02.22	Pfizer and BioNTech Initiate Rolling Submission for Emergency Use Authorization of Their COVID-19 Vaccine in Children 6 Months Through 4 Years of Age Following Request From U.S. FDA (Businesswire)
01.02.22	Pfizer To Seek FDA Approval For COVID Vaccine In Children Under 5 Years (RTTNews)
01.02.22	Pfizer Announces New Chief Development Officer (Businesswire)
31.01.22	Why Ionis Pharma Stock Falling In Pre-market? (RTTNews)
31.01.22	Pfizer and Ionis announce discontinuation of vupanorsen clinical development program (PR Newswire)
28.01.22	EU Okays Pfizer's Lorviqua As First-Line Treatment For ALK-Positive Advanced Lung Cancer (RTTNews)
28.01.22	European Commission Approves LORVIQUA® (lorlatinib) as a First-Line Treatment for ALK-Positive Advanced Lung Cancer (Businesswire)
27.01.22	Pfizer Obtains CHMP Positive Opinion For COVID-19 Oral Treatment (RTTNews)
27.01.22	Pfizer Receives CHMP Positive Opinion for Novel COVID-19 Oral Treatment (Businesswire)
25.01.22	Pfizer, BioNTech Start Omicron-specific Vaccine Trial In Adults Aged 15 To 55 (RTTNews)
25.01.22	Pfizer and BioNTech Initiate Study to Evaluate Omicron-Based COVID-19 Vaccine in Adults 18 to 55 Years of Age (Businesswire)
24.01.22	Trian Fund Management Reportedly Acquires Stake In Unilever (RTTNews)
21.01.22	Pfizer and OPKO Provide Update on the Biologics License Application for Somatrogon for Pediatric Growth Hormone Deficiency (Businesswire)
18.01.22	Health Canada Approves PAXLOVID - Quick Facts (RTTNews)
17.01.22	Unilever Intends To Materially Expand Its Presence In Health, Beauty, And Hygiene (RTTNews)
17.01.22	Bloomberg: Unilever Considers Increasing Offer For GSK Consumer Healthcare (RTTNews)
14.01.22	U.S. FDA Approves Pfizer’s CIBINQO® (abrocitinib) for Adults with Moderate-to-Severe Atopic Dermatitis (Businesswire)
12.01.22	Pfizer Unveils Positive Results From Phase 3 Study Of Prevnar 20 (RTTNews)
12.01.22	Positive Top-Line Results of Pfizer’s Phase 3 Study Exploring Coadministration of PREVNAR 20™ With Pfizer-BioNTech COVID-19 Vaccine in Older Adults Released (Businesswire)
10.01.22	Pfizer's Omicron-Specific Vaccine To Be Ready In March (RTTNews)
10.01.22	Pfizer Reaches Deal With Acuitas For Lipid Nanoparticle Delivery System For Use In MRNA Vaccines (RTTNews)
10.01.22	Pfizer, Beam Announce Up To $1.35 Bln, Exclusive Multi-year, Research Collaboration (RTTNews)
10.01.22	Pfizer Enters into Agreement with Acuitas Therapeutics for Lipid Nanoparticle Delivery System for Use in mRNA Vaccines and Therapeutics (Businesswire)
10.01.22	Pfizer and Beam Enter Exclusive Multi-Target Research Collaboration to Advance Novel In Vivo Base Editing Programs for a Range of Rare Diseases (Businesswire)
10.01.22	Form 3 78003 (RSS)
06.01.22	CDC Recommends Pfizer's Booster Dose For Children Between 12-15 Years (RTTNews)
05.01.22	CDC Recommends Pfizer Booster Shot At 5 Months; Additional Dose For Immunocompromised Children (RTTNews)
05.01.22	Biohaven, Pfizer Announce Successful Closing Of Collaboration Agreements - Quick Facts (RTTNews)
05.01.22	Pfizer, BioNTech Join To Develop MRNA-based Vaccine Against Shingles - Quick Facts (RTTNews)
05.01.22	Pfizer and BioNTech Sign New Global Collaboration Agreement to Develop First mRNA-based Shingles Vaccine (Businesswire)
04.01.22	Pfizer to Provide U.S. Government with an Additional 10 Million Treatment Courses of its Oral Therapy to Help Combat COVID-19 (Businesswire)
04.01.22	Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference (Businesswire)
03.01.22	FDA Expands Emergency Nod Of Booster Dose Of Pfizer COVID-19 Vaccine To Include 12yrs Of Age & Older (RTTNews)
03.01.22	Pfizer and BioNTech Receive U.S. FDA Emergency Use Authorization of COVID-19 Vaccine Booster for Individuals 12 Years of Age and Older (Businesswire)
03.01.22	Form 4 78003 (RSS)
31.12.21	U.K. Approves Pfizer's Antiviral Covid-19 Pill 'Paxlovid' (RTTNews)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Logitech Intl	74.30	1.53 %	K V
Holcim	87.38	1.49 %	K V
Roche Hldg G	251.00	1.46 %	K V
Swiss Re	130.35	1.44 %	K V
UBS Group	27.07	1.35 %	K V
Swisscom	501.00	0.52 %	K V
Lonza Grp	532.40	0.26 %	K V
Nestle	74.08	0.14 %	K V
Sonova Hldg	295.60	0.00 %	K V
Geberit	512.20	-0.39 %	K V

mehr

24.12.24		Börse New York: Dow Jones zeigt sich zum Handelsende fester
24.12.24		Zuversicht in New York: Dow Jones am Dienstagnachmittag mit Gewinnen
24.12.24		AstraZeneca-Aktie dennoch fester: AstraZeneca und Daiichi Sankyo rudern bei EU-Zulassungsantrag für Lungenkrebsmittel zurück
24.12.24		Börse Europa in Grün: STOXX 50 steigt schlussendlich
24.12.24		Dienstagshandel in London: Letztendlich Gewinne im FTSE 100
24.12.24		Freundlicher Handel: Letztendlich Gewinne im Euro STOXX 50
24.12.24		Dow Jones 30 Industrial-Papier Merck-Aktie: So viel Verlust hätte ein Merck-Investment von vor einem Jahr eingefahren

24.12.24

Börse New York: Dow Jones zeigt sich zum Handelsende fester

24.12.24

Zuversicht in New York: Dow Jones am Dienstagnachmittag mit Gewinnen

24.12.24

AstraZeneca-Aktie dennoch fester: AstraZeneca und Daiichi Sankyo rudern bei EU-Zulassungsantrag für Lungenkrebsmittel zurück

24.12.24

Börse Europa in Grün: STOXX 50 steigt schlussendlich

24.12.24

Dienstagshandel in London: Letztendlich Gewinne im FTSE 100

24.12.24

Freundlicher Handel: Letztendlich Gewinne im Euro STOXX 50